{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:55:22Z","timestamp":1790618122359,"version":"4.1.0"},"reference-count":468,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease and is closely associated with obesity, insulin resistance, and the recently conceptualized cardiovascular\u2013kidney\u2013metabolic syndrome. For decades, the pathogenesis of steatosis has been viewed primarily through the lens of insulin and the canonical transcriptional programs it regulates\u2014sterol regulatory element-binding protein 1c, carbohydrate response element-binding protein, peroxisome proliferator-activated receptors, and AMP-activated protein kinase. At the same time, recent data point to the existence of a complex network of non-canonical regulators that, independently of insulin, significantly modulate hepatic lipid metabolism. This review systematizes information on the fibroblast growth factors FGF21 and FGF19, adipokines (adiponectin, leptin), apolipoprotein C-III, as well as the monoamine neurotransmitters serotonin and dopamine. These molecules act within the interorgan axes \u201cliver\u2013adipose tissue,\u201d \u201cgut\u2013liver,\u201d \u201cbrain\u2013liver,\u201d and \u201cliver\u2013spleen,\u201d coordinating lipolysis, gluconeogenesis, very-low-density lipoprotein secretion, inflammation, and fibrogenesis. Disruption of the dynamic balance between canonical and non-canonical regulators is central to the progression from simple steatosis to steatohepatitis and fibrosis. The clinical translation of this concept has already begun: the thyroid hormone receptor \u03b2 agonist resmetirom and the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide have received regulatory approval for specific categories of patients with noncirrhotic metabolic dysfunction-associated steatohepatitis and fibrosis, while FGF21 and FGF19 analogs, the dual glucose-dependent insulinotropic polypeptide (GIP)\/GLP-1 agonist tirzepatide, and agents targeting apolipoprotein C-III are at various stages of clinical development or are being used for related metabolic indications. Expanding the insulin-centric paradigm to include non-canonical axes opens up new diagnostic and therapeutic possibilities for MASLD.<\/jats:p>","DOI":"10.3390\/ijms27198614","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:50:54Z","timestamp":1790614254000},"page":"8614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the \u201cLiver\u2013Other Organs\u201d Axes"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-2692","authenticated-orcid":false,"given":"Stanislav","family":"Kotlyarov","sequence":"first","affiliation":[{"name":"Department of Nursing, Ryazan State Medical University, 390026 Ryazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0676-7558","authenticated-orcid":false,"given":"Anna","family":"Kotlyarova","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Pharmacy Practice Administration, Ryazan State Medical University, 390026 Ryazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Catanzaro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Marotta","sequence":"additional","affiliation":[{"name":"Regenera R&D International for Aging Intervention, 20154 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wild, S.H., Lazarus, J.V., Spearman, C.W., Ocama, P., Bilson, J., Zhou, X.-D., Zheng, M.-H., and Byrne, C.D. (2026). MASLD Prevalence, Incidence and Global Aspects. Diabetologia.","DOI":"10.1007\/s00125-026-06726-1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11901-026-00746-6","article-title":"The Global Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease: Regional Hotspots, Trends, and Future Projections","volume":"25","author":"Alqahtani","year":"2026","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mustafa, A., Kite, C., Lagojda, L., Dallaway, A., Chatha, K.K., Than, N.N., Kassi, E., Kyrou, I., and Randeva, H.S. (2025). Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311275"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100526","DOI":"10.1016\/j.clinme.2025.100526","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"25","author":"Hsu","year":"2025","journal-title":"Clin. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global Prevalence of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis","volume":"72","author":"Ang","year":"2023","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e13564","DOI":"10.1111\/1753-0407.13564","article-title":"Prevalence of Nonalcoholic Fatty Liver Disease and Liver Cirrhosis in Chinese Adults with Type 2 Diabetes Mellitus","volume":"16","author":"Han","year":"2024","journal-title":"J. Diabetes"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Beyazal Polat, H., Beyazal, M., Arpa, M., K\u0131z\u0131lkaya, B., Ayaz, T., G\u00fcndo\u011fdu, \u00d6.L., Konur, K., Polat, Z., Beyazal \u00c7eliker, F., and Atasoy, H. (2025). Exploring the Prevalence and Risk Factors of MASLD in Patients with Newly Diagnosed Diabetes Mellitus: A Comprehensive Investigation. J. Clin. Med., 14.","DOI":"10.3390\/jcm14103513"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes","volume":"12","author":"Valerio","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dua, A., Kumari, R., Singh, M., Kumar, R., Pradeep, S., Ojesina, A.I., and Kumar, R. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Interplay of Gut Microbiome, Insulin Resistance, and Diabetes. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1618275"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_13","first-page":"815","article-title":"Mechanism of Metabolic Dysfunction-Associated Steatotic Liver Disease: Important Role of Lipid Metabolism","volume":"12","author":"Feng","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/apt.18451","article-title":"Meta-Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"61","author":"Owrangi","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease: Heterogeneous Pathomechanisms and Effectiveness of Metabolism-Based Treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1001365","DOI":"10.37349\/emed.2025.1001365","article-title":"The Transition from NAFLD to MASLD: Implications for Diagnosis, Prognosis, and Clinical Management","volume":"6","author":"Acierno","year":"2025","journal-title":"Explor. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Winterfeldt, K., and Siddiqi, S.A. (2026). The Liver at the Crossroads: Orchestrating Lipoprotein Dynamics and Lipid Homeostasis. Livers, 6.","DOI":"10.3390\/livers6010006"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Fang, H., Li, Q., Wang, H., Ren, Y., Zhang, L., and Yang, L. (2024). Maternal Nutrient Metabolism in the Liver during Pregnancy. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1295677"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s43556-025-00321-3","article-title":"Cholesterol Metabolism: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets","volume":"6","author":"Cui","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"754067","DOI":"10.1155\/2012\/754067","article-title":"Bile Acid Signaling in Liver Metabolism and Diseases","volume":"2012","author":"Li","year":"2012","journal-title":"J. Lipids"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/clockssleep5030034","article-title":"Timing Matters: The Interplay between Early Mealtime, Circadian Rhythms, Gene Expression, Circadian Hormones, and Metabolism\u2014A Narrative Review","volume":"5","author":"BaHammam","year":"2023","journal-title":"Clocks Sleep"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70132","DOI":"10.1002\/edm2.70132","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances","volume":"8","author":"Miller","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11901-026-00732-y","article-title":"MASLD Beyond the Liver: A Systemic Driver of Cardiovascular, Renal, and Oncologic Risk","volume":"25","author":"Liguori","year":"2026","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.hlc.2025.08.009","article-title":"Connecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome","volume":"34","author":"Goodheart","year":"2025","journal-title":"Heart Lung Circ."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Batta, A., De, A., Goyal, O., and Sohal, A. (2026). Editorial: The MASLD Spectrum: An Emerging Epidemic of Cardiometabolic and Extra-Hepatic Dimensions. Front. Epidemiol., 6.","DOI":"10.3389\/fepid.2026.1893613"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jacc.2025.12.015","article-title":"MASLD, MASH, and the CKM Spectrum: A Roadmap for Multiorgan Clinical Trial Design","volume":"87","author":"Zannad","year":"2026","journal-title":"JACC"},{"key":"ref_30","first-page":"e85813","article-title":"Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Interlinked Pathophysiology and Integrated Management Approach","volume":"17","year":"2025","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Nzobokela, J., Muchaili, L., Mwambungu, A., Masenga, S.K., and Kirabo, A. (2025). Pathophysiology and Emerging Biomarkers of Cardiovascular-Renal-Hepato-Metabolic Syndrome. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1661563"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kim, B.S., Kim, H.-J., Kim, H., Lee, J., Ahn, S.B., Shin, J.-H., and Lim, Y.-H. (2025). Hepatic Steatosis in Cardiovascular-Kidney-Metabolic Syndrome: Fatty Liver Index as a Predictor of Cardiovascular Outcomes. Eur. J. Prev. Cardiol., zwaf396.","DOI":"10.1093\/eurjpc\/zwaf396"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1128\/MCB.01584-12","article-title":"Insulin Inhibits Lipolysis in Adipocytes via the Evolutionarily Conserved mTORC1-Egr1-ATGL-Mediated Pathway","volume":"33","author":"Chakrabarti","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2042018819877300","DOI":"10.1177\/2042018819877300","article-title":"Update on the Synergistic Effect of HSL and Insulin in the Treatment of Metabolic Disorders","volume":"10","author":"Lan","year":"2019","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"964","DOI":"10.4093\/dmj.2025.0644","article-title":"Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications","volume":"49","author":"Truong","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1002\/j.2040-4603.2023.tb00269.x","article-title":"Insulin Regulation of Hepatic Lipid Homeostasis","volume":"13","author":"Uehara","year":"2023","journal-title":"Compr. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2010.01275.x","article-title":"Hepatic Steatosis: A Role for de Novo Lipogenesis and the Transcription Factor SREBP-1c","volume":"12","author":"Foufelle","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic Selective Insulin Resistance at the Intersection of Insulin Signaling and Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tem.2012.09.005","article-title":"Dissociating Fatty Liver and Diabetes","volume":"24","author":"Sun","year":"2013","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1172\/JCI10842","article-title":"Obesity and Insulin Resistance","volume":"106","author":"Kahn","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/dc20-1644","article-title":"Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease","volume":"44","author":"Vatner","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ramatchandirin, B., Pearah, A., and He, L. (2023). Regulation of Liver Glucose and Lipid Metabolism by Transcriptional Factors and Coactivators. Life, 13.","DOI":"10.3390\/life13020515"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kim, T.H., Hong, D.-G., and Yang, Y.M. (2021). Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121903"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"De C\u00f3l, J.P., de Lima, E.P., Pompeu, F.M., Cressoni Ara\u00fajo, A., de Alvares Goulart, R., Bechara, M.D., Laurindo, L.F., M\u00e9ndez-S\u00e1nchez, N., and Barbalho, S.M. (2024). Underlying Mechanisms behind the Brain\u2013Gut\u2013Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073694"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1042\/CS20257571","article-title":"The Physiology of MASLD: Molecular Pathways between Liver and Adipose Tissues","volume":"139","author":"Lee","year":"2025","journal-title":"Clin. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOL.0000000000000599","article-title":"Fibroblast Growth Factors in Control of Lipid Metabolism: From Biological Function to Clinical Application","volume":"30","author":"Struik","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Henriksson, E., and Andersen, B. (2020). FGF19 and FGF21 for the Treatment of NASH\u2014Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.601349"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3803\/EnM.2021.1331","article-title":"Serotonergic Regulation of Hepatic Energy Metabolism","volume":"36","author":"Park","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrm4074","article-title":"Transcriptional Regulation of Hepatic Lipogenesis","volume":"16","author":"Wang","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3803\/EnM.2017.32.1.6","article-title":"The SCAP\/SREBP Pathway: A Mediator of Hepatic Steatosis","volume":"32","author":"Moon","year":"2017","journal-title":"Endocrinol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2011.06.002","article-title":"Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways","volume":"14","author":"Yecies","year":"2011","journal-title":"Cell Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1507\/endocrj.K07E-110","article-title":"ChREBP: A Glucose-Activated Transcription Factor Involved in the Development of Metabolic Syndrome","volume":"55","author":"Iizuka","year":"2008","journal-title":"Endocr. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cmet.2006.06.008","article-title":"Carbohydrate Response Element Binding Protein, ChREBP, a Transcription Factor Coupling Hepatic Glucose Utilization and Lipid Synthesis","volume":"4","author":"Uyeda","year":"2006","journal-title":"Cell Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-0033-1358523","article-title":"Transcriptional Control of Hepatic Lipid Metabolism by SREBP and ChREBP","volume":"33","author":"Xu","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Fan, Q., N\u00f8rgaard, R.C., Bindesb\u00f8ll, C., Lucas, C., Dalen, K.T., Babaie, E., Itkonen, H.M., Matthews, J., Nebb, H.I., and Gr\u00f8nning-Wang, L.M. (2017). LXR\u03b1 Regulates Hepatic ChREBP\u03b1 Activity and Lipogenesis upon Glucose, but Not Fructose Feeding in Mice. Nutrients, 9.","DOI":"10.3390\/nu9070678"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.tem.2016.06.005","article-title":"The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis","volume":"27","author":"Herman","year":"2016","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Muriel, P., L\u00f3pez-S\u00e1nchez, P., and Ramos-Tovar, E. (2021). Fructose and the Liver. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136969"},{"key":"ref_58","first-page":"490","article-title":"Fructose and Liver Function\u2014Is This behind Nonalcoholic Liver Disease?","volume":"18","author":"Jin","year":"2015","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Federico, A., Rosato, V., Masarone, M., Torre, P., Dallio, M., Romeo, M., and Persico, M. (2021). The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. Nutrients, 13.","DOI":"10.3390\/nu13041314"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Iizuka, K. (2023). Recent Progress on Fructose Metabolism\u2014Chrebp, Fructolysis, and Polyol Pathway. Nutrients, 15.","DOI":"10.3390\/nu15071778"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1194\/jlr.M081836","article-title":"Interplay between ChREBP and SREBP-1c Coordinates Postprandial Glycolysis and Lipogenesis in Livers of Mice","volume":"59","author":"Linden","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De Novo Lipogenesis in the Liver in Health and Disease: More than Just a Shunting Yard for Glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chandrasekaran, P., and Weiskirchen, R. (2024). The Role of SCAP\/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021109"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular Mechanism of PPAR\u03b1 Action and Its Impact on Lipid Metabolism, Inflammation and Fibrosis in Non-Alcoholic Fatty Liver Disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Monroy-Ramirez, H.C., Galicia-Moreno, M., Sandoval-Rodriguez, A., Meza-Rios, A., Santos, A., and Armendariz-Borunda, J. (2021). PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158298"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"549101","DOI":"10.1155\/2010\/549101","article-title":"AMPK-Dependent Metabolic Regulation by PPAR Agonists","volume":"2010","author":"Lee","year":"2010","journal-title":"PPAR Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1074\/jbc.M605023200","article-title":"The Liver X Receptor (LXR) and Hepatic Lipogenesis. The Carbohydrate-Response Element-Binding Protein Is a Target Gene of LXR","volume":"282","author":"Cha","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1038\/s41467-026-69736-y","article-title":"GCN5 Drives MASLD Progression through LXR\u03b1\/SREBP1c Signaling Pathway\u2013Mediated de Novo Lipogenesis","volume":"17","author":"Xiao","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","article-title":"Selective versus Total Insulin Resistance: A Pathogenic Paradox","volume":"7","author":"Brown","year":"2008","journal-title":"Cell Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcmgh.2018.10.016","article-title":"Resolving the Paradox of Hepatic Insulin Resistance","volume":"7","author":"Santoleri","year":"2018","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of Insulin Signaling Pathway in Rat Liver: mTORC1 Required for Stimulation of Lipogenesis, but Not Inhibition of Gluconeogenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1073\/pnas.1000323107","article-title":"mTORC1 Activates SREBP-1c and Uncouples Lipogenesis from Gluconeogenesis","volume":"107","author":"Laplante","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Palihaderu, P.A.D.S., Mendis, B.I.L.M., Premarathne, J.M.K.J.K., Dias, W.K.R.R., Yeap, S.K., Ho, W.Y., Dissanayake, A.S., Rajapakse, I.H., Karunanayake, P., and Senarath, U. (2022). Potential Role of microRNAs in Selective Hepatic Insulin Resistance: From Paradox to the Paradigm. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1028846"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Nigi, L., Grieco, G.E., Ventriglia, G., Brusco, N., Mancarella, F., Formichi, C., Dotta, F., and Sebastiani, G. (2018). MicroRNAs as Regulators of Insulin Signaling: Research Updates and Potential Therapeutic Perspectives in Type 2 Diabetes. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123705"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ncrna.2023.02.005","article-title":"Regulation and Mechanism of Action of miRNAs on Insulin Resistance in Skeletal Muscles","volume":"8","author":"Beilerli","year":"2023","journal-title":"Non-Coding RNA Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrm3313","article-title":"MicroRNAs in Metabolism and Metabolic Disorders","volume":"13","author":"Rottiers","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., and An, Z. (2023). Unmasking the Enigma of Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanism to the Clinic. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1294267"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.apsb.2025.01.010","article-title":"The Ubiquitin\u2013Proteasome System: A Potential Target for the MASLD","volume":"15","author":"Liu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"155912","DOI":"10.1016\/j.metabol.2024.155912","article-title":"Deciphering the Molecular Pathways of Saroglitazar: A Dual PPAR \u03b1\/\u03b3 Agonist for Managing Metabolic NAFLD","volume":"155","author":"Ezhilarasan","year":"2024","journal-title":"Metabolism"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41581-018-0078-3","article-title":"The Klotho Proteins in Health and Disease","volume":"15","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Itoh, N., Ohta, H., and Konishi, M. (2015). Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy. Front. Endocrinol., 6.","DOI":"10.3389\/fendo.2015.00154"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4614-0887-1_1","article-title":"The Structural Biology of the FGF19 Subfamily","volume":"728","author":"Beenken","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12967-016-0821-0","article-title":"Regulation of Fibroblast Growth Factor 15\/19 and 21 on Metabolism: In the Fed or Fasted State","volume":"14","author":"Guan","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Torres-Oteros, D., Nicola-Llorente, M., Sanz-Lamora, H., P\u00e9rez-Mart\u00ed, A., Marrero, P.F., Canudas, S., Haro, D., and Relat, J. (2026). Hepatic FGF21 Deletion Improves Glucose Metabolism, Alters Lipogenic and Chrna4 Gene Expression, and Enhances Telomere Maintenance in Aged Female Mice. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27010194"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Falamarzi, K., Malekpour, M., Tafti, M.F., Azarpira, N., Behboodi, M., and Zarei, M. (2022). The Role of FGF21 and Its Analogs on Liver Associated Diseases. Front. Med., 9.","DOI":"10.3389\/fmed.2022.967375"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic Messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"560034","DOI":"10.2147\/DDDT.S560034","article-title":"Fibroblast Growth Factor 21: Mechanisms, Therapeutic Potential, and Clinical Translation in Metabolic Dysfunction","volume":"20","author":"Rama","year":"2026","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Casta\u00f1\u00e9, H., Jim\u00e9nez-Franco, A., Onoiu, A.-I., Cambra-Cort\u00e9s, V., Hern\u00e1ndez-Aguilera, A., Parada, D., Riu, F., Zorzano, A., Camps, J., and Joven, J. (2025). Dysregulation of the FGF21\u2013Adiponectin Axis in a Large Cohort of Patients with Severe Obesity and Liver Disease. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202507.1768.v1"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"109331","DOI":"10.1016\/j.celrep.2021.109331","article-title":"FGF21 Promotes Thermogenic Gene Expression as an Autocrine Factor in Adipocytes","volume":"35","author":"Zhang","year":"2021","journal-title":"Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cmet.2017.09.005","article-title":"FGF19, FGF21 and an FGFR1\/\u03b2-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia","volume":"26","author":"Lan","year":"2017","journal-title":"Cell Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"101564","DOI":"10.1016\/j.molmet.2022.101564","article-title":"Pharmacological FGF21 Signals to Glutamatergic Neurons to Enhance Leptin Action and Lower Body Weight during Obesity","volume":"64","author":"Claflin","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/a-1778-4159","article-title":"FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance","volume":"54","year":"2022","journal-title":"Horm. Metab. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102877","DOI":"10.1016\/j.redox.2023.102877","article-title":"FGF21 Alleviates Adipose Stem Cell Senescence via CD90 Glycosylation-Dependent Glucose Influx in Remodeling Healthy White Adipose Tissue","volume":"67","author":"Zhou","year":"2023","journal-title":"Redox Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s11033-026-12132-y","article-title":"The Role of Fibroblast Growth Factor 21 in Diabetes and Metabolic Dysfunction","volume":"53","author":"Jaiswal","year":"2026","journal-title":"Mol. Biol. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/cvr\/cvab076","article-title":"Pharmacological Treatment with FGF21 Strongly Improves Plasma Cholesterol Metabolism to Reduce Atherosclerosis","volume":"118","author":"Liu","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s44318-023-00008-x","article-title":"Brown Adipose Tissue CoQ Deficiency Activates the Integrated Stress Response and FGF21-Dependent Mitohormesis","volume":"43","author":"Chang","year":"2024","journal-title":"EMBO J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41434-023-00422-0","article-title":"Long-Term Effects of a Fat-Directed FGF21 Gene Therapy in Aged Female Mice","volume":"31","author":"Anderson","year":"2024","journal-title":"Gene Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","article-title":"FGF21 Reverses MASH through Coordinated Actions on the CNS and Liver","volume":"37","author":"Rose","year":"2025","journal-title":"Cell Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e83075","DOI":"10.7554\/eLife.83075","article-title":"FGF21 Protects against Hepatic Lipotoxicity and Macrophage Activation to Attenuate Fibrogenesis in Nonalcoholic Steatohepatitis","volume":"12","author":"Liu","year":"2023","journal-title":"eLife"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3892\/br.2017.890","article-title":"Metabolic Role of Fibroblast Growth Factor 21 in Liver, Adipose and Nervous System Tissues","volume":"6","author":"Lin","year":"2017","journal-title":"Biomed. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Tillman, E.J., and Rolph, T. (2020). FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.601290"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.tem.2026.01.007","article-title":"Targeting Ferroptosis to Halt MASLD and MASH","volume":"37","author":"Wang","year":"2026","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/15578518261427700","article-title":"Fibroblast Growth Factor 21 Resistance and Metabolic Dysfunction\u2013Associated Steatotic Liver Disease","volume":"24","author":"Post","year":"2026","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.tem.2021.08.008","article-title":"Stress-Induced FGF21 and GDF15 in Obesity and Obesity Resistance","volume":"32","author":"Keipert","year":"2021","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"E292","DOI":"10.1152\/ajpendo.00101.2017","article-title":"Fibroblast Growth Factor 21: A Regulator of Metabolic Disease and Health Span","volume":"313","author":"Xie","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Chen, Z., Yang, L., Liu, Y., Huang, P., Song, H., and Zheng, P. (2022). The Potential Function and Clinical Application of FGF21 in Metabolic Diseases. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1089214"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e174164","DOI":"10.1172\/jci.insight.174164","article-title":"Intestinal FGF15 Regulates Bile Acid and Cholesterol Metabolism but Not Glucose and Energy Balance","volume":"9","author":"Shin","year":"2024","journal-title":"JCI Insight"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MOL.0000000000000060","article-title":"Regulation of Bile Acid Homeostasis by the Intestinal Diet1\u2013FGF15\/19 Axis","volume":"25","author":"Reue","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Katafuchi, T., and Makishima, M. (2022). Molecular Basis of Bile Acid-FXR-FGF15\/19 Signaling Axis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116046"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile Acid Metabolism in Liver Pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1038\/s41467-021-24914-y","article-title":"Intestinal-Derived FGF15 Protects against Deleterious Effects of Vertical Sleeve Gastrectomy in Mice","volume":"12","author":"Shin","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tem.2014.10.002","article-title":"Tissue-Specific Actions of the Metabolic Hormones FGF15\/19 and FGF21","volume":"26","author":"Owen","year":"2015","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 Regulates Hepatic Glucose Metabolism By Inhibiting the CREB-PGC-1\u03b1 Pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/hep.29676","article-title":"Modulation of the Intestinal Bile Acid\u2013FXR\u2013FGF15 Axis Improves Alcoholic Liver Disease in Mice","volume":"67","author":"Hartmann","year":"2018","journal-title":"Hepatology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s40168-023-01709-5","article-title":"Gut Microbiota-Bile Acid Crosstalk Regulates Murine Lipid Metabolism via the Intestinal FXR-FGF19 Axis in Diet-Induced Humanized Dyslipidemia","volume":"11","author":"Xu","year":"2023","journal-title":"Microbiome"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5114\/aoms.2013.33181","article-title":"Biochemistry of Adipose Tissue: An Endocrine Organ","volume":"9","author":"Coelho","year":"2013","journal-title":"Arch. Med. Sci. AMS"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.mce.2009.08.018","article-title":"Adipose Tissue as an Endocrine Organ","volume":"316","author":"Galic","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"loae003","DOI":"10.1093\/lifemeta\/loae003","article-title":"The Secretory Function of Adipose Tissues in Metabolic Regulation","volume":"3","author":"Liu","year":"2024","journal-title":"Life Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/j.2040-4603.2018.tb00036.x","article-title":"Adiponectin Regulation and Function","volume":"8","author":"Fang","year":"2018","journal-title":"Compr. Physiol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Clemente-Su\u00e1rez, V.J., Redondo-Fl\u00f3rez, L., Beltr\u00e1n-Velasco, A.I., Mart\u00edn-Rodr\u00edguez, A., Mart\u00ednez-Guardado, I., Navarro-Jim\u00e9nez, E., Laborde-C\u00e1rdenas, C.C., and Tornero-Aguilera, J.F. (2023). The Role of Adipokines in Health and Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051290"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Wu, O., Lu, X., Leng, J., Zhang, X., Liu, W., Yang, F., Zhang, H., Li, J., Khederzadeh, S., and Liu, X. (2024). Reevaluating Adiponectin\u2019s Impact on Obesity Hypertension: A Chinese Case-Control Study. BMC Cardiovasc. Disord., 24.","DOI":"10.1186\/s12872-024-03865-4"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1463-1326.2005.00510.x","article-title":"Adiponectin--a Key Adipokine in the Metabolic Syndrome","volume":"8","author":"Whitehead","year":"2006","journal-title":"Diabetes Obes. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Choi, H.M., Doss, H.M., and Kim, K.S. (2020). Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041219"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Begum, M., Choubey, M., Tirumalasetty, M.B., Arbee, S., Mohib, M.M., Wahiduzzaman, M., Mamun, M.A., Uddin, M.B., and Mohiuddin, M.S. (2023). Adiponectin: A Promising Target for the Treatment of Diabetes and Its Complications. Life, 13.","DOI":"10.20944\/preprints202310.0782.v1"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.molmet.2017.01.002","article-title":"Inducible Overexpression of Adiponectin Receptors Highlight the Roles of Adiponectin-Induced Ceramidase Signaling in Lipid and Glucose Homeostasis","volume":"6","author":"Holland","year":"2017","journal-title":"Mol. Metab."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.molmet.2017.01.011","article-title":"Adiponectin Serenades Ceramidase to Improve Metabolism","volume":"6","author":"Febbraio","year":"2017","journal-title":"Mol. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.27134","article-title":"Is the Adiponectin-AMPK-Mitochondrial Axis Involved in Progression of Nonalcoholic Fatty Liver Disease?","volume":"60","author":"Dasarathy","year":"2014","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Fang, C., Pan, J., Qu, N., Lei, Y., Han, J., Zhang, J., and Han, D. (2022). The AMPK Pathway in Fatty Liver Disease. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.970292"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13293-023-00543-6","article-title":"Sex Differences in Obesity-Induced Renal Lipid Accumulation Revealed by Lipidomics: A Role of Adiponectin\/AMPK Axis","volume":"14","author":"Juszczak","year":"2023","journal-title":"Biol. Sex Differ."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Kim, Y., and Park, C.W. (2019). Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071782"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"509","DOI":"10.47162\/RJME.62.2.17","article-title":"Systemic and Adipose Tissue Inflammation in NASH: Correlations with Histopathological Aspects","volume":"62","author":"Micu","year":"2021","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3748\/wjg.v19.i6.802","article-title":"What Is the Role of Adiponectin in Obesity Related Non-Alcoholic Fatty Liver Disease?","volume":"19","author":"Finelli","year":"2013","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_136","first-page":"2801","article-title":"Adiponectin, a Key Adipokine in Obesity Related Liver Diseases","volume":"17","author":"Buechler","year":"2011","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"20406223251378868","DOI":"10.1177\/20406223251378868","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Comorbidity in COPD","volume":"16","author":"Ghanem","year":"2025","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/s41467-019-10684-1","article-title":"Brain Leptin Reduces Liver Lipids by Increasing Hepatic Triglyceride Secretion and Lowering Lipogenesis","volume":"10","author":"Hackl","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Kim, M.-H., and Kim, H. (2021). Role of Leptin in the Digestive System. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.660040"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-U\u00f1a, M., L\u00f3pez-Manche\u00f1o, Y., Di\u00e9guez, C., Fern\u00e1ndez-Rojo, M.A., and Novelle, M.G. (2020). Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249368"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.cmet.2022.09.020","article-title":"Leptin Increases Hepatic Triglyceride Export via a Vagal Mechanism in Humans","volume":"34","author":"Metz","year":"2022","journal-title":"Cell Metab."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"R566","DOI":"10.1152\/ajpregu.00180.2013","article-title":"Selective Leptin Resistance Revisited","volume":"305","author":"Mark","year":"2013","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e250521","DOI":"10.1530\/EC-25-0521","article-title":"Leptin and Leptin Resistance in Obesity: Current Evidence, Mechanisms and Future Directions","volume":"14","author":"Hu","year":"2025","journal-title":"Endocr. Connect."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s42255-021-00515-3","article-title":"Histone Deacetylase 6 Inhibition Restores Leptin Sensitivity and Reduces Obesity","volume":"4","author":"Hadley","year":"2022","journal-title":"Nat. Metab."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/jhep.2002.32029","article-title":"Leptin in Hepatic Fibrosis: Evidence for Increased Collagen Production in Stellate Cells and Lean Littermates of Ob\/Ob Mice","volume":"35","author":"Saxena","year":"2002","journal-title":"Hepatology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0168-8278(02)00102-2","article-title":"Leptin Is Essential for the Hepatic Fibrogenic Response to Chronic Liver Injury","volume":"37","author":"Leclercq","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13578-023-01124-1","article-title":"Modelling Porcine NAFLD by Deletion of Leptin and Defining the Role of AMPK in Hepatic Fibrosis","volume":"13","author":"Tan","year":"2023","journal-title":"Cell Biosci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tem.2015.01.002","article-title":"Adipocytokines and Hepatic Fibrosis","volume":"26","author":"Saxena","year":"2015","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/jcb.22634","article-title":"Adiponectin Activation of AMPK Disrupts Leptin-Mediated Hepatic Fibrosis via Suppressors of Cytokine Signaling (SOCS-3)","volume":"110","author":"Handy","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Liu, Y., Li, Y., Liang, J., Sun, Z., Wu, Q., Liu, Y., and Sun, C. (2021). The Mechanism of Leptin on Inhibiting Fibrosis and Promoting Browning of White Fat by Reducing ITGA5 in Mice. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212353"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/hep.32569","article-title":"Lipocalin-2 Activates Hepatic Stellate Cells and Promotes Nonalcoholic Steatohepatitis in High-fat Diet\u2013Fed Ob\/Ob Mice","volume":"77","author":"Kim","year":"2023","journal-title":"Hepatology"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Farstad-O\u2019Halloran, K., Sooda, A., Iqbal, T., Wilton, S., and Aung-Htut, M.T. (2025). Discovery of Novel APOC3 Isoforms in Hepatic and Intestinal Cell Models Using Long-Read RNA Sequencing. Genes, 16.","DOI":"10.3390\/genes16040412"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Bor\u00e9n, J., Packard, C.J., and Taskinen, M.-R. (2020). The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00474"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/cvr\/cvad177","article-title":"Exploring Apolipoprotein C-III: Pathophysiological and Pharmacological Relevance","volume":"119","author":"Packard","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: Understanding an Emerging Cardiovascular Risk Factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin. Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target Populations for Novel Triglyceride-Lowering Therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11883-023-01080-8","article-title":"APOC-III: A Gatekeeper in Controlling Triglyceride Metabolism","volume":"25","author":"Giammanco","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MED.0000000000000136","article-title":"ApoC-III: A Potent Modulator of Hypertriglyceridemia and Cardiovascular Disease","volume":"22","author":"Kohan","year":"2015","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"De Luca, C., Ciciola, P., D\u2019Errico, G., Di Taranto, M.D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Di Minno, M., and Calcaterra, I. (2025). Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review. Genes, 16.","DOI":"10.3390\/genes16111377"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","article-title":"Updates in Drug Treatment of Severe Hypertriglyceridemia","volume":"25","author":"Schwarz","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"101238","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-Associated Fatty Liver Disease and Lipoprotein Metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","article-title":"APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk","volume":"38","author":"Wulff","year":"2018","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease","volume":"371","author":"Nordestgaard","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"119114","DOI":"10.1016\/j.atherosclerosis.2025.119114","article-title":"Familial Chylomicronemia Syndrome and Treatments to Target Hepatic APOC3 mRNA","volume":"403","author":"Brinton","year":"2025","journal-title":"Atherosclerosis"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40261-025-01484-1","article-title":"Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine","volume":"45","author":"Zhang","year":"2025","journal-title":"Clin. Drug Investig."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Jamal, F., Elshaer, A., Odeh, N.B., Alatout, M.H., Shahin, T., Worden, A.R., Albunni, H.N., Lizaola-Mayo, B.C., Jayasekera, C.R., and Chascsa, D.M.H. (2025). Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Life, 15.","DOI":"10.3390\/life15081306"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"6430023","DOI":"10.1155\/ije\/6430023","article-title":"Resmetirom: The First Disease-Specific Treatment for MASH","volume":"2025","author":"Mousa","year":"2025","journal-title":"Int. J. Endocrinol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Knezovi\u0107, E., Hefer, M., Bla\u017eanovi\u0107, S., Petrovi\u0107, A., Tomi\u010di\u0107, V., Srb, N., Kirner, D., Smoli\u0107, R., and Smoli\u0107, M. (2025). Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47030154"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2021.08.051","article-title":"New Therapies for Lowering Triglyceride-Rich Lipoproteins","volume":"78","author":"Rosenson","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"156187","DOI":"10.1016\/j.metabol.2025.156187","article-title":"Apolipoprotein C-III Inhibitors for the Treatment of Hypertriglyceridemia: A Meta-Analysis of Randomized Controlled Trials","volume":"167","author":"Mendes","year":"2025","journal-title":"Metabolism"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Chen, Y., Xu, J., and Chen, Y. (2021). Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders. Nutrients, 13.","DOI":"10.3390\/nu13062099"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The Expanded Biology of Serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1038\/s41467-018-07287-7","article-title":"Serotonin Signals through a Gut-Liver Axis to Regulate Hepatic Steatosis","volume":"9","author":"Choi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Wang, L., Fan, X., Han, J., Cai, M., Wang, X., Wang, Y., and Shang, J. (2020). Gut-Derived Serotonin Contributes to the Progression of Non-Alcoholic Steatohepatitis via the Liver HTR2A\/PPAR\u03b32 Pathway. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00553"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"798","DOI":"10.4093\/dmj.2024.0215","article-title":"Serotonin Regulates Lipogenesis and Endoplasmic Reticulum Stress in Alcoholic Liver Disease","volume":"49","author":"Hwang","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"loae039","DOI":"10.1093\/lifemeta\/loae039","article-title":"Serotonin Signaling to Regulate Energy Metabolism: A Gut Microbiota Perspective","volume":"4","author":"Li","year":"2024","journal-title":"Life Metab."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"102826","DOI":"10.1016\/j.copbio.2022.102826","article-title":"Towards Manipulating Serotonin Signaling via the Microbiota-Gut-Brain Axis","volume":"78","author":"Everett","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"G29","DOI":"10.1152\/ajpgi.00240.2025","article-title":"Microbial Dysbiosis Alters Serotonin Signaling in a Post-Inflammatory Murine Model of Visceral Pain","volume":"330","author":"Roth","year":"2026","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"dmm049612","DOI":"10.1242\/dmm.049612","article-title":"Involvement of the Liver-Gut Peripheral Neural Axis in Nonalcoholic Fatty Liver Disease Pathologies via Hepatic HTR2A","volume":"15","author":"Owaki","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41467-024-44874-3","article-title":"Discovery of a Peripheral 5HT2A Antagonist as a Clinical Candidate for Metabolic Dysfunction-Associated Steatohepatitis","volume":"15","author":"Pagire","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Tavares, G., Martins, F.O., Melo, B.F., Matafome, P., and Conde, S.V. (2021). Peripheral Dopamine Directly Acts on Insulin-Sensitive Tissues to Regulate Insulin Signaling and Metabolic Function. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.713418"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"101241","DOI":"10.1016\/j.molmet.2021.101241","article-title":"Dopamine D2 Receptor Agonist, Bromocriptine, Remodels Adipose Tissue Dopaminergic Signalling and Upregulates Catabolic Pathways, Improving Metabolic Profile in Type 2 Diabetes","volume":"51","author":"Tavares","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1758-5996-6-104","article-title":"Neuroendocrine and Metabolic Components of Dopamine Agonist Amelioration of Metabolic Syndrome in SHR Rats","volume":"6","author":"Ezrokhi","year":"2014","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/oby.24068","article-title":"Dopamine in the Regulation of Glucose and Lipid Metabolism: A Narrative Review","volume":"32","author":"Li","year":"2024","journal-title":"Obesity"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Lelou, E., Corlu, A., Nesseler, N., Rauch, C., Mall\u00e9dant, Y., Seguin, P., and Aninat, C. (2022). The Role of Catecholamines in Pathophysiological Liver Processes. Cells, 11.","DOI":"10.3390\/cells11061021"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"108617","DOI":"10.3748\/wjg.v31.i34.108617","article-title":"Dopamine Receptor D1-Mediated Suppression of Liver Fibrosis via Hippo\/Yes-Associated Protein 1 Signaling in Levodopa Treatment","volume":"31","author":"Wang","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s12276-022-00766-4","article-title":"Upregulation of the Serine Palmitoyltransferase Subunit SPTLC2 by Endoplasmic Reticulum Stress Inhibits the Hepatic Insulin Response","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.aav3722","article-title":"Targeting a Ceramide Double Bond Improves Insulin Resistance and Hepatic Steatosis","volume":"365","author":"Chaurasia","year":"2019","journal-title":"Science"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.cell.2019.05.008","article-title":"CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity","volume":"177","author":"Hammerschmidt","year":"2019","journal-title":"Cell"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cmet.2014.09.015","article-title":"CerS2 Haploinsufficiency Inhibits \u03b2-Oxidation and Confers Susceptibility to Diet-Induced Steatohepatitis and Insulin Resistance","volume":"20","author":"Raichur","year":"2014","journal-title":"Cell Metab."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"eaai7905","DOI":"10.1126\/scisignal.aai7905","article-title":"The Glucocorticoid-Angptl4-Ceramide Axis Induces Insulin Resistance through PP2A and PKC\u03b6","volume":"10","author":"Chen","year":"2017","journal-title":"Sci. Signal."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"114746","DOI":"10.1016\/j.celrep.2024.114746","article-title":"Ceramide Synthesis Inhibitors Prevent Lipid-Induced Insulin Resistance through the DAG-PKC\u03b5-Insulin receptorT1150 Phosphorylation Pathway","volume":"43","author":"Xu","year":"2024","journal-title":"Cell Rep."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"eadp5540","DOI":"10.1126\/science.adp5540","article-title":"A Symbiotic Filamentous Gut Fungus Ameliorates MASH via a Secondary Metabolite\u2013CerS6\u2013Ceramide Axis","volume":"388","author":"Zhou","year":"2025","journal-title":"Science"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2337\/dc17-1318","article-title":"Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis","volume":"41","author":"Apostolopoulou","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2021.04.013","article-title":"Hepatic Lipidomic Remodeling in Severe Obesity Manifests with Steatosis and Does Not Evolve with Non-Alcoholic Steatohepatitis","volume":"75","author":"Ooi","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1161\/ATVBAHA.120.315530","article-title":"Ceramide Scores Predict Cardiovascular Risk in the Community","volume":"41","author":"Vasile","year":"2021","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Osawa, Y., Kawai, H., Nakashima, K., Nakaseko, Y., Suto, D., Yanagida, K., Hashidate-Yoshida, T., Mori, T., Yoshio, S., and Ohtake, T. (2024). Sphingosine-1-Phosphate Promotes Liver Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0303296"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-023-01845-0","article-title":"Liraglutide Reduces Plasma Dihydroceramide Levels in Patients with Type 2 Diabetes","volume":"22","author":"Denimal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/db15-0941","article-title":"Mesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance","volume":"65","author":"Wueest","year":"2016","journal-title":"Diabetes"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrm2391","article-title":"Adipocyte Dysfunctions Linking Obesity to Insulin Resistance and Type 2 Diabetes","volume":"9","author":"Guilherme","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","article-title":"Crosstalk between Adipose Tissue Insulin Resistance and Liver Macrophages in Non-Alcoholic Fatty Liver Disease","volume":"71","author":"Rosso","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"100434","DOI":"10.1016\/j.jlr.2023.100434","article-title":"Acute Activation of Adipocyte Lipolysis Reveals Dynamic Lipid Remodeling of the Hepatic Lipidome","volume":"65","author":"Zhang","year":"2023","journal-title":"J. Lipid Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jcmgh.2021.07.008","article-title":"White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice","volume":"12","author":"Sakane","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Rasineni, K., Jordan, C.W., Thomes, P.G., Kubik, J.L., Staab, E.M., Sweeney, S.A., Talmon, G.A., Donohue, T.M., McNiven, M.A., and Kharbanda, K.K. (2021). Contrasting Effects of Fasting on Liver-Adipose Axis in Alcohol-Associated and Non-Alcoholic Fatty Liver. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.625352"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The Gut-Liver Axis in Liver Disease: Pathophysiological Basis for Therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile Acid Receptors FXR and TGR5 Signaling in Fatty Liver Diseases and Therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic Acid Alleviates Non-Alcoholic Fatty Liver Disease through Modulating the Gut-Liver Axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1111\/1751-7915.14293","article-title":"Akkermansia Muciniphila Alleviates High-fat-diet-related Metabolic-associated Fatty Liver Disease by Modulating Gut Microbiota and Bile Acids","volume":"16","author":"Wu","year":"2023","journal-title":"Microb. Biotechnol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1927633","DOI":"10.1080\/19490976.2021.1927633","article-title":"Gut Akkermansia Muciniphila Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease by Regulating the Metabolism of L-Aspartate via Gut-Liver Axis","volume":"13","author":"Rao","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e186423","DOI":"10.1172\/JCI186423","article-title":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease and the Gut Microbiome: Pathogenic Insights and Therapeutic Innovations","volume":"135","author":"Schnabl","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2200597","DOI":"10.1002\/mnfr.202200597","article-title":"Butyrate Attenuates Hepatic Steatosis Induced by a High-Fat and Fiber-Deficient Diet via the Hepatic GPR41\/43-CaMKII\/HDAC1-CREB Pathway","volume":"67","author":"Zheng","year":"2023","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41522-023-00451-y","article-title":"Inulin-Enriched Megamonas Funiformis Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease by Producing Propionic Acid","volume":"9","author":"Yang","year":"2023","journal-title":"npj Biofilms Microbiomes"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s40168-021-01125-7","article-title":"Commensal Microbe-Derived Acetate Suppresses NAFLD\/NASH Development via Hepatic FFAR2 Signalling in Mice","volume":"9","author":"Aoki","year":"2021","journal-title":"Microbiome"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.13500","article-title":"The Effects of Dietary Supplementation with Inulin and Inulin-propionate Ester on Hepatic Steatosis in Adults with Non-alcoholic Fatty Liver Disease","volume":"21","author":"Chambers","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cmet.2025.11.015","article-title":"Dual Inhibition of ACLY and ACSS2 by EVT0185 Reduces Steatosis, Hepatic Stellate Cell Activation, and Fibrosis in Mouse Models of MASH","volume":"38","author":"Gautam","year":"2026","journal-title":"Cell Metab."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Mitrovi\u0107, M., Stankovi\u0107 Popovi\u0107, V., Erceg, S., Peri\u0161i\u0107 Mitrovi\u0107, M., Dobrosavljevi\u0107, A., Stupar, A., Vukovi\u0107, P., Zlatkovi\u0107, D., and Svorcan, P. (2025). Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202504.0157.v1"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e180943","DOI":"10.1172\/jci.insight.180943","article-title":"Circulating Metabolite Signatures Indicate Differential Gut-Liver Crosstalk in Lean and Obese MASLD","volume":"10","author":"Haag","year":"2025","journal-title":"JCI Insight"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2307568","DOI":"10.1080\/19490976.2024.2307568","article-title":"Gut Microbiota-Derived Indole Compounds Attenuate Metabolic Dysfunction-Associated Steatotic Liver Disease by Improving Fat Metabolism and Inflammation","volume":"16","author":"Min","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"RP87458","DOI":"10.7554\/eLife.87458.3","article-title":"Oral Supplementation of Gut Microbial Metabolite Indole-3-Acetate Alleviates Diet-Induced Steatosis and Inflammation in Mice","volume":"12","author":"Ding","year":"2024","journal-title":"eLife"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Sehgal, R., Ilha, M., Vaittinen, M., Kaminska, D., M\u00e4nnist\u00f6, V., K\u00e4rj\u00e4, V., Tuomainen, M., Hanhineva, K., Romeo, S., and Pajukanta, P. (2021). Indole-3-Propionic Acid, a Gut-Derived Tryptophan Metabolite, Associates with Hepatic Fibrosis. Nutrients, 13.","DOI":"10.3390\/nu13103509"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep.31115","article-title":"Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2-Kinase\/Fructose-2,6-Biphosphatase 3","volume":"72","author":"Ma","year":"2020","journal-title":"Hepatology"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"111960","DOI":"10.1016\/j.cellsig.2025.111960","article-title":"The FMO3\/TMAO\/HSP90\u03b2 Axis Aggravates MAFLD by Disrupting Mitochondrial Protein Homeostasis","volume":"134","author":"Guo","year":"2025","journal-title":"Cell. Signal."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Theofilis, P., Vordoni, A., and Kalaitzidis, R.G. (2022). Trimethylamine N-Oxide Levels in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Metabolites, 12.","DOI":"10.3390\/metabo12121243"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/liv.14963","article-title":"Circulating Trimethylamine- N -oxide Is Associated with All-cause Mortality in Subjects with Nonalcoholic Fatty Liver Disease","volume":"41","author":"Post","year":"2021","journal-title":"Liver Int."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1900257","DOI":"10.1002\/mnfr.201900257","article-title":"Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease","volume":"63","author":"Tan","year":"2019","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000358312","article-title":"Hormonal Control of Metabolism by the Hypothalamus-Autonomic Nervous System-Liver Axis","volume":"42","author":"Kalsbeek","year":"2014","journal-title":"Front. Horm. Res."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.beem.2014.05.001","article-title":"Hypothalamic Control of Hepatic Lipid Metabolism via the Autonomic Nervous System","volume":"28","author":"Bruinstroop","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Gallardo, N., Artigas-Jer\u00f3nimo, S., Mazuecos, L., and Andr\u00e9s, A. (2025). Neuroendocrine Control of Glucose Homeostasis: Integrative Mechanisms from the Hypothalamus to the Brainstem. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1731725"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Hwang, J., Okada, J., Liu, L., Pessin, J.E., Schwartz, G.J., and Jo, Y.-H. (2024). The Development of Hepatic Steatosis Depends on the Presence of Liver-Innervating Parasympathetic Cholinergic Neurons in Mice Fed a High-Fat Diet. PLoS Biol., 22.","DOI":"10.1371\/journal.pbio.3002865"},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Cincotta, A.H. (2023). Brain Dopamine\u2013Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713255"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1113\/JP281727","article-title":"Bile Acids, Bioactive Signalling Molecules in Interoceptive Gut-to-brain Communication","volume":"600","author":"Joyce","year":"2022","journal-title":"J. Physiol."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"N\u00ed Dhonnabh\u00e1\u00edn, R., Xiao, Q., and O\u2019Malley, D. (2021). Aberrant Gut-To-Brain Signaling in Irritable Bowel Syndrome\u2014The Role of Bile Acids. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.745190"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"119467","DOI":"10.3748\/wjg.119467","article-title":"Liver-Spleen Axis: Deciphering a Crucial Crosstalk in Non-Alcoholic Fatty Liver Disease Progression and Therapeutic Implications","volume":"32","author":"Tarantino","year":"2026","journal-title":"World J. Gastroenterol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"112518","DOI":"10.1016\/j.mce.2025.112518","article-title":"The Spleen-Liver Axis Supports Obesity-Induced Systemic and Fatty Liver Inflammation via MDSC and NKT Cell Enrichment","volume":"601","author":"Brummer","year":"2025","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"e28123","DOI":"10.1016\/j.heliyon.2024.e28123","article-title":"Spleen Volume Is Independently Associated with Non-Alcoholic Fatty Liver Disease, Liver Volume and Liver Fibrosis","volume":"10","author":"Helgesson","year":"2024","journal-title":"Heliyon"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40477-024-00965-x","article-title":"The Correlation between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Grades and Hemodynamic Alterations of the Portal, Hepatic, and Splenic Vein and Spleen Size","volume":"28","author":"Borji","year":"2024","journal-title":"J. Ultrasound"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cgh.2022.01.007","article-title":"Spleen Size Does Not Correlate With Histological Stage of Liver Disease in People With Nonalcoholic Fatty Liver Disease","volume":"21","author":"Cacciottolo","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/db11-1688","article-title":"A Novel Anti-Inflammatory Role for Spleen-Derived Interleukin-10 in Obesity-Induced Inflammation in White Adipose Tissue and Liver","volume":"61","author":"Gotoh","year":"2012","journal-title":"Diabetes"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/1319-3767.161641","article-title":"Nonalcoholic Fatty Liver Disease Progression in Rats Is Accelerated by Splenic Regulation of Liver PTEN\/AKT","volume":"21","author":"Wang","year":"2015","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/hep.32782","article-title":"CD11b+CD43hiLy6Clo Splenocyte-derived Macrophages Exacerbate Liver Fibrosis via Spleen\u2013Liver Axis","volume":"77","author":"Zhang","year":"2023","journal-title":"Hepatology"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41588-026-02660-5","article-title":"Metabolically and Epigenetically Reprogrammed Splenic TRNP1hiCD8+ T Cells Exacerbate Liver Fibrosis","volume":"58","author":"Zhang","year":"2026","journal-title":"Nat. Genet."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"RP91367","DOI":"10.7554\/eLife.91367.3","article-title":"Plasma Growth Hormone Pulses Induce Male-Biased Pulsatile Chromatin Opening and Epigenetic Regulation in Adult Mouse Liver","volume":"12","author":"Rampersaud","year":"2023","journal-title":"eLife"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"bqac046","DOI":"10.1210\/endocr\/bqac046","article-title":"Constitutively Active STAT5b Feminizes Mouse Liver Gene Expression","volume":"163","author":"Ma","year":"2022","journal-title":"Endocrinology"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"101143","DOI":"10.1016\/j.jhepr.2024.101143","article-title":"Hepatic Estrogen Receptor Alpha Drives Masculinization in Post-Menopausal Women with Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"6","author":"Meda","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","article-title":"Interaction between Estrogen Receptor-\u03b1 and PNPLA3 p.I148M Variant Drives Fatty Liver Disease Susceptibility in Women","volume":"29","author":"Cherubini","year":"2023","journal-title":"Nat. Med."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-Analysis","volume":"19","author":"Balakrishnan","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/GME.0000000000002133","article-title":"Menopause Is Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"30","author":"Jaroenlapnopparat","year":"2023","journal-title":"Menopause"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"e70121","DOI":"10.1002\/dmrr.70121","article-title":"Earlier Menopause and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Global Cohort Study","volume":"42","author":"Stokar","year":"2026","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"e1689","DOI":"10.1210\/clinem\/dgae363","article-title":"FGF21 Mediating the Sex-Dependent Response to Dietary Macronutrients","volume":"109","author":"Ryan","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Xu, J., Shao, X., Zeng, H., Wang, C., Li, J., Peng, X., Zhuo, Y., Hua, L., Meng, F., and Han, X. (2023). Hepatic-Specific FGF21 Knockout Abrogates Ovariectomy-Induced Obesity by Reversing Corticosterone Production. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914922"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"101472","DOI":"10.1016\/j.jhepr.2025.101472","article-title":"Consistent Improvements in Liver Histology across Subgroups in a Post Hoc Analysis of the SYNERGY-NASH Trial with Tirzepatide","volume":"7","author":"Hartman","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0000000000000927","article-title":"Lipid Metabolism during Pregnancy: Consequences for Mother and Child","volume":"35","author":"Mulder","year":"2024","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Yang, L., Meng, Y., Shi, Y., Fang, H., and Zhang, L. (2023). Maternal Hepatic Immunology during Pregnancy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1220323"},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Buell-Acosta, J.D., Garces, M.F., Parada-Ba\u00f1os, A.J., Angel-Muller, E., Paez, M.C., Eslava-Schmalbach, J., Escobar-Cordoba, F., Caminos-Cepeda, S.A., Lacunza, E., and Casta\u00f1o, J.P. (2022). Maternal Fibroblast Growth Factor 21 Levels Decrease during Early Pregnancy in Normotensive Pregnant Women but Are Higher in Preeclamptic Women\u2014A Longitudinal Study. Cells, 11.","DOI":"10.3390\/cells11142251"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"103238","DOI":"10.1016\/j.eclinm.2025.103238","article-title":"Adverse Pregnancy and Birth Outcomes in Women with Biopsy-Proven MASLD: A Nationwide Cohort Study","volume":"83","author":"Marxer","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3350\/cmh.2021.0205","article-title":"Systematic Review with Meta-Analysis: Non-Alcoholic Fatty Liver Disease and the Association with Pregnancy Outcomes","volume":"28","author":"Eslick","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41467-023-36981-4","article-title":"Gut Microbiota Alters Host Bile Acid Metabolism to Contribute to Intrahepatic Cholestasis of Pregnancy","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of Fatty Acids Stored in Liver and Secreted via Lipoproteins in Patients with Nonalcoholic Fatty Liver Disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin Resistance Drives Hepatic de Novo Lipogenesis in Nonalcoholic Fatty Liver Disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"100250","DOI":"10.1016\/j.jlr.2022.100250","article-title":"Elevated de Novo Lipogenesis, Slow Liver Triglyceride Turnover, and Clinical Correlations in Nonalcoholic Steatohepatitis Patients","volume":"63","author":"Lawitz","year":"2022","journal-title":"J. Lipid Res."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"e174233","DOI":"10.1172\/JCI174233","article-title":"Weight Loss in MASLD Restores the Balance of Liver Fatty Acid Sources","volume":"135","author":"Lambert","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/dom.12272","article-title":"Abdominal Subcutaneous Adipose Tissue Insulin Resistance and Lipolysis in Patients with Non-alcoholic Steatohepatitis","volume":"16","author":"Armstrong","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","article-title":"Contribution of Hepatic de Novo Lipogenesis and Reesterification of Plasma Non Esterified Fatty Acids to Plasma Triglyceride Synthesis during Non-Alcoholic Fatty Liver Disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metab."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1210\/clinem\/dgac660","article-title":"Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD","volume":"108","author":"Kalavalapalli","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of Adipose Tissue Insulin Resistance on Metabolic Parameters and Liver Histology in Obese Patients with Nonalcoholic Fatty Liver Disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1210\/jc.2019-00875","article-title":"Hepatic Fatty Acid Balance and Hepatic Fat Content in Humans With Severe Obesity","volume":"104","author":"Lytle","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1210\/jc.2015-3476","article-title":"Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease","volume":"101","author":"Poulsen","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jhep.2021.02.027","article-title":"Fructose- and Sucrose- but Not Glucose-Sweetened Beverages Promote Hepatic de Novo Lipogenesis: A Randomized Controlled Trial","volume":"75","author":"Hochuli","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1053\/j.gastro.2017.05.043","article-title":"Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity","volume":"153","author":"Schwarz","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de Novo Fatty Acid Synthesis to Hepatic Steatosis and Insulin Resistance: Lessons from Genetically Engineered Mice","volume":"118","author":"Postic","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI41636","article-title":"The Lipogenic Transcription Factor ChREBP Dissociates Hepatic Steatosis from Insulin Resistance in Mice and Humans","volume":"122","author":"Benhamed","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Adolph, T.E., Grander, C., Grabherr, F., and Tilg, H. (2017). Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081649"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"153994","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast Growth Factor 21 in Non-Alcoholic Fatty Liver Disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metabolism"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","article-title":"An Adipocentric Perspective on the Development and Progression of Non-Alcoholic Fatty Liver Disease","volume":"78","author":"Lee","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_278","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Cortegana, C., Garc\u00eda-Galey, A., Tami, M., del Pino, P., Carmona, I., L\u00f3pez, S., Alba, G., and S\u00e1nchez-Margalet, V. (2021). Role of Leptin in Non-Alcoholic Fatty Liver Disease. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070762"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/164_2019_228","article-title":"Pharmacologic Modulation of Bile Acid-FXR-FGF15\/19 Pathway for the Treatment of Non-Alcoholic Steatohepatitis","volume":"256","author":"Schumacher","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_280","doi-asserted-by":"crossref","unstructured":"Friedrich, D., Marschall, H.-U., and Lammert, F. (2018). Response of Fibroblast Growth Factor 19 and Bile Acid Synthesis after a Body Weight-Adjusted Oral Fat Tolerance Test in Overweight and Obese NAFLD Patients: A Non-Randomized Controlled Pilot Trial. BMC Gastroenterol., 18.","DOI":"10.1186\/s12876-018-0805-z"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbadis.2015.10.028","article-title":"Osteopontin Is a Proximal Effector of Leptin-Mediated Non-Alcoholic Steatohepatitis (NASH) Fibrosis","volume":"1862","author":"Coombes","year":"2016","journal-title":"Biochim. Biophys. Acta BBA-Mol. Basis Dis."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40139-015-0094-y","article-title":"Adiponectin as an Anti-Fibrotic and Anti-Inflammatory Adipokine in the Liver","volume":"3","author":"Park","year":"2015","journal-title":"Curr. Pathobiol. Rep."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"32584","DOI":"10.1073\/pnas.1922169117","article-title":"Mechanisms by Which Adiponectin Reverses High Fat Diet-Induced Insulin Resistance in Mice","volume":"117","author":"Li","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ueg2.12534","article-title":"Fibroblast Growth Factor 21 Is a Hepatokine Involved in MASLD Progression","volume":"12","author":"Ampuero","year":"2024","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00125-015-3769-3","article-title":"Circulating Leptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"59","author":"Polyzos","year":"2016","journal-title":"Diabetologia"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum Total Adiponectin in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed Hepatic Bile Acid Signalling despite Elevated Production of Primary and Secondary Bile Acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ijo.2014.76","article-title":"Opposite Alterations in FGF21 and FGF19 Levels and Disturbed Expression of the Receptor Machinery for Endocrine FGFs in Obese Patients","volume":"39","author":"Catalan","year":"2015","journal-title":"Int. J. Obes."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"100745","DOI":"10.1016\/j.gastha.2025.100745","article-title":"Beta-Klotho Protein Expression in Healthy Human Tissues and Liver Biopsies From Patients With MASLD or MASH","volume":"4","author":"Aaldijk","year":"2025","journal-title":"Gastro Hep Adv."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/gut.2003.037010","article-title":"Adiponectin and Its Receptors in Non-Alcoholic Steatohepatitis","volume":"54","author":"Kaser","year":"2005","journal-title":"Gut"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11695-010-0353-2","article-title":"Hepatic Expression of Adiponectin Receptors Increases with Non-Alcoholic Fatty Liver Disease Progression in Morbid Obesity in Correlation with Glutathione Peroxidase 1","volume":"21","author":"Carazo","year":"2011","journal-title":"Obes. Surg."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/en.2012-1193","article-title":"TNF-\u03b1 Represses \u03b2-Klotho Expression and Impairs FGF21 Action in Adipose Cells: Involvement of JNK1 in the FGF21 Pathway","volume":"153","author":"Hondares","year":"2012","journal-title":"Endocrinology"},{"key":"ref_293","doi-asserted-by":"crossref","unstructured":"Emamgholipour, S., Esmaeili, F., Shabani, M., Hasanpour, S.Z., Pilehvari, M., Zabihi-Mahmoudabadi, H., Motevasseli, M., and Shanaki, M. (2023). Alterations of SOCS1 and SOCS3 Transcript Levels, but Not Promoter Methylation Levels in Subcutaneous Adipose Tissues in Obese Women. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-022-01247-5"},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"De la Cruz-Color, L., Dominguez-Rosales, J.A., Maldonado-Gonz\u00e1lez, M., Ru\u00edz-Madrigal, B., S\u00e1nchez Mu\u00f1oz, M.P., Zaragoza-Guerra, V.A., Espinoza-Padilla, V.H., Ruelas-Cinco, E.d.C., Ram\u00edrez-Meza, S.M., and Torres Baranda, J.R. (2024). Evidence That Peripheral Leptin Resistance in Omental Adipose Tissue and Liver Correlates with MASLD in Humans. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126420"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2337\/db10-1684","article-title":"Endoplasmic Reticulum Stress Inhibits STAT3-Dependent Suppression of Hepatic Gluconeogenesis via Dephosphorylation and Deacetylation","volume":"61","author":"Kimura","year":"2012","journal-title":"Diabetes"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/a-2549-6889","article-title":"Association of FGF21 with Metabolic and Cardiovascular Diseases: A Mendelian Randomization Analysis","volume":"133","author":"He","year":"2025","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s40001-023-01147-x","article-title":"Association between Leptin and NAFLD: A Two-Sample Mendelian Randomization Study","volume":"28","author":"Guo","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.2337\/db13-0128","article-title":"Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes","volume":"62","author":"Yaghootkar","year":"2013","journal-title":"Diabetes"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature21065","article-title":"Single-Cell Spatial Reconstruction Reveals Global Division of Labor in the Mammalian Liver","volume":"542","author":"Halpern","year":"2017","journal-title":"Nature"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41586-026-10377-y","article-title":"A Spatial Atlas of the Healthy Human Liver from Live Donors","volume":"653","author":"Yakubovsky","year":"2026","journal-title":"Nature"},{"key":"ref_301","doi-asserted-by":"crossref","unstructured":"Paolini, E., Meroni, M., Longo, M., Badiali, S., Maggioni, M., Fracanzani, A.L., and Dongiovanni, P. (2026). The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27031601"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"100599","DOI":"10.1016\/j.jlr.2024.100599","article-title":"Spatial Lipidomics Reveals Zone-Specific Hepatic Lipid Alteration and Remodeling in Metabolic Dysfunction-Associated Steatohepatitis","volume":"65","author":"Seubnooch","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-024-07465-2","article-title":"Acquisition of Epithelial Plasticity in Human Chronic Liver Disease","volume":"630","author":"Gribben","year":"2024","journal-title":"Nature"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cell.2025.11.031","article-title":"Hepatic Adaptation to Chronic Metabolic Stress Primes Tumorigenesis","volume":"189","author":"Tzouanas","year":"2026","journal-title":"Cell"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the Fibrotic Niche of Human Liver Cirrhosis at Single-Cell Level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial Proteogenomics Reveals Distinct and Evolutionarily Conserved Hepatic Macrophage Niches","volume":"185","author":"Guilliams","year":"2022","journal-title":"Cell"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s41590-025-02255-y","article-title":"Single-Cell Atlas of Human Liver and Blood Immune Cells across Fatty Liver Disease Stages Reveals Distinct Signatures Linked to Liver Dysfunction and Fibrogenesis","volume":"26","author":"Martin","year":"2025","journal-title":"Nat. Immunol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jhep.2022.06.004","article-title":"Soluble TREM2 Levels Reflect the Recruitment and Expansion of TREM2+ Macrophages That Localize to Fibrotic Areas and Limit NASH","volume":"77","author":"Hendrikx","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.immuni.2025.05.013","article-title":"Spatially Restricted and Ontogenically Distinct Hepatic Macrophages Are Required for Tissue Repair","volume":"58","author":"Bujko","year":"2025","journal-title":"Immunity"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1038\/s41588-025-02407-8","article-title":"Spatially Resolved Multi-Omics of Human Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"57","author":"Li","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.jhepr.2021.100278","article-title":"Single-Cell RNA Sequencing of Human Liver Reveals Hepatic Stellate Cell Heterogeneity","volume":"3","author":"Payen","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.10.044","article-title":"Multi-Modal Analysis of Human Hepatic Stellate Cells Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"82","author":"Kim","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of Liver Sinusoidal Endothelial Cells in Non-Alcoholic Fatty Liver Disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/jgh.15926","article-title":"Circulating Adiponectin in Patients with Nonalcoholic Fatty Liver Disease-related Liver Fibrosis: A Systematic Review and a Meta-analysis","volume":"37","author":"Tontikidou","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1096\/fj.04-1847fje","article-title":"Leptin as a Novel Profibrogenic Cytokine in Hepatic Stellate Cells: Mitogenesis and Inhibition of Apoptosis Mediated by Extracellular Regulated Kinase (Erk) and Akt Phosphorylation","volume":"18","author":"Saxena","year":"2004","journal-title":"FASEB J."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"eads9470","DOI":"10.1126\/scitranslmed.ads9470","article-title":"Resolving Fibrosis by Stimulating HSC-Dependent Extracellular Matrix Degradation","volume":"17","author":"Sharma","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s42255-026-01476-1","article-title":"PLIN5 Phosphorylation Orchestrates Mitochondria Lipid-Droplet Coupling to Control Hepatic Lipid Flux and Steatosis","volume":"8","author":"Kang","year":"2026","journal-title":"Nat. Metab."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-020-2101-7","article-title":"Dietary Fructose Feeds Hepatic Lipogenesis via Microbiota-Derived Acetate","volume":"579","author":"Zhao","year":"2020","journal-title":"Nature"},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00018-024-05507-6","article-title":"GLP-1 and GIP Agonism Has No Direct Actions in Human Hepatocytes or Hepatic Stellate Cells","volume":"81","author":"Cabaleiro","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"eadx2681","DOI":"10.1126\/sciadv.adx2681","article-title":"Targeted Inhibition of Hepatic de Novo Ceramide Synthesis Ameliorates MASH","volume":"11","author":"Yu","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_321","doi-asserted-by":"crossref","unstructured":"Carli, F., Sabatini, S., Gaggini, M., Sironi, A.M., Bedogni, G., and Gastaldelli, A. (2023). Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914651"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1097\/CM9.0000000000001890","article-title":"The Role of FGF21 in the Pathogenesis of Cardiovascular Disease","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin. Med. J."},{"key":"ref_323","doi-asserted-by":"crossref","unstructured":"Shawa, F., Izzeddin, F., and Koc, G. (2026). Circulating Fibroblast Growth Factor-21 in Coronary Artery Disease: A Systematic Review and Meta-Analysis. Ir. J. Med. Sci.","DOI":"10.1007\/s11845-026-04472-2"},{"key":"ref_324","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Yan, J., Yang, N., Qian, Z., Nie, H., Yang, Z., Yan, D., Wei, X., Ruan, L., and Huang, Y. (2021). High-Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.705273"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2018.10.011","article-title":"Association of Elevated Circulating Fibroblast Growth Factor 21 Levels with Prevalent and Incident Metabolic Syndrome: The Multi-Ethnic Study of Atherosclerosis","volume":"281","author":"Ong","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_327","doi-asserted-by":"crossref","unstructured":"Yang, M., Liu, C., Jiang, N., Liu, Y., Luo, S., Li, C., Zhao, H., Han, Y., Chen, W., and Li, L. (2023). Fibroblast Growth Factor 21 in Metabolic Syndrome. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1220426"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1210\/clinem\/dgac729","article-title":"Circulating FGF21 Concentration, Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results From the PREVEND Study","volume":"108","author":"Post","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_329","doi-asserted-by":"crossref","unstructured":"Liu, Z., Peng, Y., Li, S., Lin, Y., Huang, Y., Chen, W., Bao, C., Zhou, Z., Lin, Z., and Chen, L. (2023). Increased Circulating FGF21 Level Predicts the Burden of Metabolic Demands and Risk of Vascular Diseases in Adults with Type 2 Diabetes. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-023-01523-y"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.atherosclerosis.2016.11.033","article-title":"The Role of Fibroblast Growth Factor 21 in Atherosclerosis","volume":"257","author":"Kokkinos","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"2500689","DOI":"10.1080\/07853890.2025.2500689","article-title":"Circulating Fibroblast Growth Factor 21 Is Associated with Blood Pressure in the Chinese Population: A Community-Based Study","volume":"57","author":"Zhen","year":"2025","journal-title":"Ann. Med."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"155616","DOI":"10.1016\/j.metabol.2023.155616","article-title":"Renoprotective Effects of Genetically Proxied Fibroblast Growth Factor 21: Mendelian Randomization, Proteome-Wide and Metabolome-Wide Association Study","volume":"145","author":"Giontella","year":"2023","journal-title":"Metab. Clin. Exp."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"2179336","DOI":"10.1080\/0886022X.2023.2179336","article-title":"Fibroblast Growth Factor 21 May Be a Strong Biomarker for Renal Outcomes: A Meta-Analysis","volume":"45","author":"Yong","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"2171030","DOI":"10.1080\/14756366.2023.2171030","article-title":"Adiponectin\u2014Stratification Biomarker in Diastolic Cardiac Dysfunction","volume":"38","author":"Diaconu","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_335","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., Kreouzi, M., Hitas, C., Anagnostou, D., and Nikolaou, M. (2024). Adipokines and Cardiometabolic Heart Failure with Preserved Ejection Fraction: A State-of-the-Art Review. Diagnostics, 14.","DOI":"10.3390\/diagnostics14232677"},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1038\/s41598-020-62465-2","article-title":"High Serum Adiponectin as a Biomarker of Renal Dysfunction: Results from the KNOW-CKD Study","volume":"10","author":"Song","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_337","doi-asserted-by":"crossref","unstructured":"Yang, H.S., Kim, S.-N., Ro, J.-H., and Hur, M. (2025). Adiponectin and All-Cause Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Metabolites, 15.","DOI":"10.3390\/metabo15040230"},{"key":"ref_338","first-page":"63","article-title":"Adiponectin and Chronic Kidney Disease; a Review on Recent Findings","volume":"4","author":"Heidari","year":"2015","journal-title":"J. Nephropharmacology"},{"key":"ref_339","doi-asserted-by":"crossref","unstructured":"Przybyci\u0144ski, J., Dziedziejko, V., Pucha\u0142owicz, K., Doma\u0144ski, L., and Pawlik, A. (2020). Adiponectin in Chronic Kidney Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249375"},{"key":"ref_340","doi-asserted-by":"crossref","unstructured":"Kuo, I.-C., Wu, P.-H., Lin, H.Y.-H., Niu, S.-W., Huang, J.-C., Hung, C.-C., Chiu, Y.-W., and Chen, H.-C. (2019). The Association of Adiponectin with Metabolic Syndrome and Clinical Outcome in Patients with Non-Diabetic Chronic Kidney Disease. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220158"},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41401-024-01466-7","article-title":"New Advances in Novel Pharmacotherapeutic Candidates for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) between 2022 and 2024","volume":"46","author":"Wong","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.pharmr.2024.100018","article-title":"Pharmacological Treatment for Metabolic Dysfunction\u2013Associated Steatotic Liver Disease and Related Disorders: Current and Emerging Therapeutic Options","volume":"77","author":"Zhang","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_343","first-page":"9","article-title":"Advances in Novel Drug Therapy for Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis","volume":"3","author":"Nasir","year":"2025","journal-title":"J. Transl. Gastroenterol."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14656566.2025.2478917","article-title":"Resmetirom: The First Approved Therapy for Treating Metabolic Dysfunction Associated Steatohepatitis","volume":"26","author":"Bhushan","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_345","first-page":"559331","article-title":"Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)","volume":"20","author":"Kleef","year":"2026","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_346","doi-asserted-by":"crossref","unstructured":"Tiwari, A., Sharma, A., Kumar, H., Gupta, V., Deshpande, V., Mupparaju, J.S., Mishra, T., Bharadwaj, H.R., Dahiya, D.S., and Jain, V. (2025). Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier. Biomedicines, 13.","DOI":"10.3390\/biomedicines13092079"},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/HEP.0000000000001084","article-title":"Health-Related Quality of Life (HRQL) Assessments in a 52-Week, Double-Blind, Randomized, Placebo-Controlled Phase III Study of Resmetirom (MGL-3196) in Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis","volume":"81","author":"Younossi","year":"2025","journal-title":"Hepatology"},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"e00913","DOI":"10.1097\/HC9.0000000000000913","article-title":"Improvement in Health-Related Quality of Life after Treatment with Resmetirom in Patients with the Spectrum of MASLD: From Early MASH to MASH Cirrhosis","volume":"10","author":"Younossi","year":"2026","journal-title":"Hepatol. Commun."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by Targeting Peroxisome Proliferator-Activated Receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The Pan-PPAR Agonist Lanifibranor Improves Cardiometabolic Health in Patients with Metabolic Dysfunction-Associated Steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR Agonist Lanifibranor Improves Insulin Resistance and Hepatic Steatosis in Patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_353","unstructured":"Inventiva Pharma (2026, September 22). A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04849728."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised Clinical Trial: Pemafibrate, a Novel Selective Peroxisome Proliferator-activated Receptor \u03b1 Modulator (SPPARM\u03b1), versus Placebo in Patients with Non-alcoholic Fatty Liver Disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Glynn","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"e70558","DOI":"10.1111\/liv.70558","article-title":"Saroglitazar 4 Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 Study","volume":"46","author":"Sanyal","year":"2026","journal-title":"Liver Int."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_359","unstructured":"(2026, September 22). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02704403."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MPG.0000000000003796","article-title":"An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis","volume":"77","author":"Goyal","year":"2023","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MS9.0000000000002868","article-title":"Latest FDA Approved Drug Elafibranor (Iqirvo): A Novel Prospect for Treatment of Primary Biliary Cholangitis","volume":"87","author":"Hasibuzzaman","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-Analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones Expand Body Fluid Volume through PPAR\u03b3 Stimulation of ENaC-Mediated Renal Salt Absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat. Med."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of Fracture with Thiazolidinediones: An Updated Meta-Analysis of Randomized Clinical Trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and Bladder Cancer Risk: A Systematic Review and Meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator\u2212Activated Receptor\u2212\u03b1 and \u2212\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of Pharmacological Therapies in Metabolic Dysfunction\u2013Associated Steatohepatitis for Fibrosis Regression and MASH Resolution: Systematic Review and Network Meta-Analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of Efruxifermin for Patients with Compensated NASH Cirrhosis","volume":"5","author":"Harrison","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_371","doi-asserted-by":"crossref","unstructured":"Wang, W., Gao, X., Niu, W., Yin, J., and He, K. (2025). Targeting Metabolism: Innovative Therapies for MASLD Unveiled. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094077"},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"560039","DOI":"10.2147\/DDDT.S560039","article-title":"Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential","volume":"20","author":"Alamgir","year":"2026","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0140-6736(25)02276-7","article-title":"Efimosfermin Alfa (BOS-580) Once per Month in People with Metabolic Dysfunction-Associated Steatohepatitis with F2 or F3 Fibrosis: Results from a 24-Week, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"407","author":"Noureddin","year":"2026","journal-title":"Lancet"},{"key":"ref_376","unstructured":"(2026, September 22). A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07221188."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin Alfa (BOS-580), a Long-Acting FGF21 Analogue, in Participants with Phenotypic Metabolic Dysfunction-Associated Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2174\/0113816128374854250709050425","article-title":"FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data","volume":"32","author":"Boutari","year":"2026","journal-title":"Curr. Pharm. Des."},{"key":"ref_379","doi-asserted-by":"crossref","unstructured":"Prikhodko, V.A., and Okovityi, S.V. (2026). Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities. Biomedicines, 14.","DOI":"10.3390\/biomedicines14040909"},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"103786","DOI":"10.1016\/j.jpet.2025.103786","article-title":"Efficacy and Safety of Fibroblast Growth Factor 21 Analogs in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease and Metabolic Dysfunction\u2013Associated Steatohepatitis: A Systematic Review and Network Meta-Analysis","volume":"393","author":"Abdeljawad","year":"2026","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_381","first-page":"e70131","article-title":"Evaluating the Effectiveness of Pegbelfermin in MASH-Associated Hepatic Fibrosis A Meta-Analysis and Systematic Review of Randomized Controlled Trials","volume":"9","author":"Shahzil","year":"2025","journal-title":"JGH Open Open Access J. Gastroenterol. Hepatol."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"102357","DOI":"10.1016\/j.clinre.2024.102357","article-title":"Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"48","author":"Marey","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in Patients with Non-Alcoholic Steatohepatitis (ALPINE 2\/3): A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.jhepr.2021.100255","article-title":"Potent Suppression of Hydrophobic Bile Acids by Aldafermin, an FGF19 Analogue, across Metabolic and Cholestatic Liver Diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Aldafermin in Patients with NASH and Compensated Cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"100913","DOI":"10.1016\/j.jpha.2023.12.003","article-title":"New Advances of Adiponectin in Regulating Obesity and Related Metabolic Syndromes","volume":"14","author":"Han","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"ref_387","doi-asserted-by":"crossref","unstructured":"Otvos, L. (2019). Potential Adiponectin Receptor Response Modifier Therapeutics. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00539"},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/ATVBAHA.117.309630","article-title":"Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin\/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice","volume":"37","author":"Sun","year":"2017","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_389","doi-asserted-by":"crossref","unstructured":"Li, W. (2022). Targeting Ceramides and Adiponectin Receptors in the Islet of Langerhans for Treating Diabetes. Molecules, 27.","DOI":"10.3390\/molecules27186117"},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-022-04726-8","article-title":"Adiponectin Receptor Agonist Ameliorates Cardiac Lipotoxicity via Enhancing Ceramide Metabolism in Type 2 Diabetic Mice","volume":"13","author":"Kim","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature12656","article-title":"A Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity","volume":"503","author":"Yamauchi","year":"2013","journal-title":"Nature"},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1111\/dom.16542","article-title":"AdipoRon Attenuates Steatosis, Inflammation and Fibrosis in Murine Diet-Induced NASH via Inhibiting ER Stress","volume":"27","author":"Nie","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"106157","DOI":"10.1016\/j.intimp.2019.106157","article-title":"Therapeutic Effects of AdipoRon on Liver Inflammation and Fibrosis Induced by CCl4 in Mice","volume":"79","author":"Sha","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"117511","DOI":"10.1016\/j.ecoenv.2024.117511","article-title":"AdipoRon Mitigates Liver Fibrosis by Suppressing Serine\/Glycine Biosynthesis through ATF4-Dependent Glutaminolysis","volume":"289","author":"Zhang","year":"2025","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"ref_395","doi-asserted-by":"crossref","unstructured":"Kumar, P., Smith, T., Rahman, K., Thorn, N.E., and Anania, F.A. (2014). Adiponectin Agonist ADP355 Attenuates CCl4-Induced Liver Fibrosis in Mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110405"},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1038\/s41598-017-04162-1","article-title":"Adiponectin Is an Endogenous Anti-Fibrotic Mediator and Therapeutic Target","volume":"7","author":"Marangoni","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"115871","DOI":"10.1016\/j.bcp.2023.115871","article-title":"AdipoRon and ADP355, Adiponectin Receptor Agonists, in Metabolic-Associated Fatty Liver Disease (MAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"218","author":"Barbalho","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"114800","DOI":"10.1016\/j.ejmech.2022.114800","article-title":"Discovery of Novel AdipoRon Analogues as Potent Anti-Inflammatory Agents against Nonalcoholic Steatohepatitis","volume":"244","author":"Dai","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1039\/D3MD00727H","article-title":"Identification of AdipoRon Analogues as Novel Activators of AMPK for the Treatment of Type 2 Diabetes","volume":"15","author":"Lin","year":"2024","journal-title":"RSC Med. Chem."},{"key":"ref_400","doi-asserted-by":"crossref","unstructured":"Milani, I., Chinucci, M., Leonetti, F., and Capoccia, D. (2025). MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women. Biomedicines, 13.","DOI":"10.3390\/biomedicines13040855"},{"key":"ref_401","doi-asserted-by":"crossref","unstructured":"Raina, M.A., Bhutani, K., Rashid, G., Khan, M.A., and Mudassar, S. (2026). Adipokine Dysregulation in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Hospital-Based Case\u2013Control Study from India. Indian J. Clin. Biochem., 1\u20139.","DOI":"10.1007\/s12291-026-01427-3"},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.cmet.2024.02.007","article-title":"Central Inhibition of HDAC6 Re-Sensitizes Leptin Signaling during Obesity to Induce Profound Weight Loss","volume":"36","author":"Guan","year":"2024","journal-title":"Cell Metab."},{"key":"ref_403","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/psc.2408","article-title":"Restoration of Leptin Responsiveness in Diet-Induced Obese Mice Using an Optimized Leptin Analog in Combination with Exendin-4 or FGF21","volume":"18","author":"Sullivan","year":"2012","journal-title":"J. Pept. Sci."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The Liver Diseases of Lipodystrophy: The Long-Term Effect of Leptin Treatment","volume":"59","author":"Zadeh","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-Term Effectiveness and Safety of Metreleptin in the Treatment of Patients with Generalized Lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"bvaf216","DOI":"10.1210\/jendso\/bvaf216","article-title":"Postmarketing Surveillance of the Safety and Effectiveness of Metreleptin in Patients with Lipodystrophy in Japan","volume":"10","author":"Ebihara","year":"2025","journal-title":"J. Endocr. Soc."},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity Associated with Metreleptin Treatment in Patients with Obesity or Lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"156261","DOI":"10.1016\/j.metabol.2025.156261","article-title":"Leptin Acutely Increases Hepatic Triglyceride Secretion in Patients with Lipodystrophy","volume":"169","author":"Beghini","year":"2025","journal-title":"Metab.-Clin. Exp."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","article-title":"The Pleiotropic Effects of Glucagon-like Peptide-1 Receptor Agonists in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Review for Gastroenterologists","volume":"34","author":"Alkhouri","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/apt.70196","article-title":"Review Article: GLP-1 Receptor Agonists and Glucagon\/GIP\/GLP-1 Receptor Dual or Triple Agonists\u2014Mechanism of Action and Emerging Therapeutic Landscape in MASLD","volume":"61","author":"Zafer","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1111\/dom.70148","article-title":"Shared Mechanistic Pathways of Glucagon Signalling: Unlocking Its Potential for Treating Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease, and Other Cardio-kidney-metabolic Conditions","volume":"27","author":"Neff","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"113937","DOI":"10.1016\/j.intimp.2024.113937","article-title":"Dual GIP and GLP-1 Receptor Agonist Tirzepatide Alleviates Hepatic Steatosis and Modulates Gut Microbiota and Bile Acid Metabolism in Diabetic Mice","volume":"147","author":"Hu","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_413","doi-asserted-by":"crossref","unstructured":"Gofron, K.K., Wasilewski, A., and Ma\u0142gorzewicz, S. (2025). Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients, 17.","DOI":"10.3390\/nu17081303"},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/bcp.70487","article-title":"GLP-1 Agonists and the Gut Microbiome: A Bidirectional Relationship","volume":"92","author":"Kamath","year":"2026","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"sfaf351","DOI":"10.1093\/ckj\/sfaf351","article-title":"Gut Microbiota Modulation in GLP-1RA and SGLT-2i Therapy: Clinical Implications and Mechanistic Insights in Type 2 Diabetes","volume":"18","author":"Kanbay","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.3748\/wjg.v30.i43.4682","article-title":"Interplay of Gut Microbiota, Glucagon-like Peptide Receptor Agonists, and Nutrition: New Frontiers in Metabolic Dysfunction-Associated Steatotic Liver Disease Therapy","volume":"30","author":"Basaranoglu","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis: November 2025 Updates to AASLD Practice Guidance","volume":"83","author":"Bansal","year":"2025","journal-title":"Hepatology"},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/dc25-1306","article-title":"Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction\u2013 Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1038\/s41591-026-04479-3","article-title":"Survodutide in Adults with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: SYNCHRONIZE-MASLD, a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"32","author":"Kaplan","year":"2026","journal-title":"Nat. Med."},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A Phase IIa Active-Comparator-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide in Patients with Non-Alcoholic Fatty Liver Disease","volume":"79","author":"Lawitz","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_423","first-page":"1847","article-title":"Safety and Efficacy of Novel Incretin Co-Agonist Cotadutide in Biopsy-Proven Noncirrhotic MASH With Fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide Safety and Efficacy in Patients with Non-Alcoholic Steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of Dulaglutide on Liver Fat in Patients with Type 2 Diabetes and NAFLD: Randomised Controlled Trial (D-LIFT Trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/oby.70155","article-title":"Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models","volume":"34","author":"Briand","year":"2026","journal-title":"Obesity"},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_428","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/HEP.0000000000001028","article-title":"Comparative Efficacy of Pharmacologic Therapies for MASH in Reducing Liver Fat Content: Systematic Review and Network Meta-Analysis","volume":"83","author":"Koh","year":"2026","journal-title":"Hepatology"},{"key":"ref_429","first-page":"e106038","article-title":"THR-\u03b2 Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty","volume":"18","author":"Alzaki","year":"2026","journal-title":"Cureus"},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.1097\/MS9.0000000000003768","article-title":"Olezarsen: FDA Approval and Clinical Impact in Familial Chylomicronemia Syndrome (FCS)","volume":"87","author":"Khan","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"ref_432","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk","volume":"392","author":"Watts","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_433","doi-asserted-by":"crossref","unstructured":"Yin, E.B., Wanat, M.A., and Wang, E.M. (2026). ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome. Ann. Pharmacother., 10600280261452675.","DOI":"10.1177\/10600280261452675"},{"key":"ref_434","doi-asserted-by":"crossref","unstructured":"Kelly, M.S., Lewis, J., Zuch, D., Rogowsky, M.R., and Dixon, D.L. (J. Cardiovasc. Pharmacol., 2026). Olezarsen and Plozasiran: Novel apoC-III Targeting Medications for the Treatment of Hypertriglyceridemia, J. Cardiovasc. Pharmacol., Epub ahead of printing.","DOI":"10.1097\/FJC.0000000000001854"},{"key":"ref_435","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_436","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia","volume":"393","author":"Bergmark","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_437","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk","volume":"394","author":"Marston","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_438","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jacc.2025.03.496","article-title":"Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia","volume":"85","author":"Ballantyne","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_439","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11883-025-01345-4","article-title":"Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease","volume":"27","author":"Tsimikas","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_440","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jdi.12526","article-title":"Effective Treatment with Combination of Peripheral 5-hydroxytryptamine Synthetic Inhibitor and 5-hydroxytryptamine 2 Receptor Antagonist on Glucocorticoid-induced Whole-body Insulin Resistance with Hyperglycemia","volume":"7","author":"Ma","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_441","doi-asserted-by":"crossref","unstructured":"Cincotta, A.H., Cersosimo, E., Alatrach, M., Ezrokhi, M., Agyin, C., Adams, J., Chilton, R., Triplitt, C., Chamarthi, B., and Cominos, N. (2022). Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative\/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23168851"},{"key":"ref_442","doi-asserted-by":"crossref","unstructured":"Ezrokhi, M., Zhang, Y., Luo, S., and Cincotta, A.H. (2021). Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116142"},{"key":"ref_443","doi-asserted-by":"crossref","first-page":"113298","DOI":"10.3748\/wjg.v31.i46.113298","article-title":"Levodopa and the Dopamine Receptor D1-Hippo\/Yes-Associated Protein Axis: A Novel Therapeutic Avenue for Liver Fibrosis","volume":"31","author":"Xie","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"ref_444","doi-asserted-by":"crossref","unstructured":"Tang, M., Ma, Y., and Wang, Y. (2026). Updating the MASH Pharmacotherapy Landscape: A Network Meta-Analysis Incorporating SGLT2 Inhibitors and Emerging Combination Therapies. Front. Endocrinol., 17.","DOI":"10.3389\/fendo.2026.1829315"},{"key":"ref_445","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12962-026-00741-0","article-title":"Semaglutide versus Resmetirom for Noncirrhotic MASH with Moderate to Advanced Fibrosis: A Cost-Effectiveness Analysis","volume":"24","author":"Njei","year":"2026","journal-title":"Cost Eff. Resour. Alloc. CE"},{"key":"ref_446","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in Compensated Liver Cirrhosis Caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_447","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40265-026-02301-5","article-title":"Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions","volume":"86","author":"Patil","year":"2026","journal-title":"Drugs"},{"key":"ref_448","first-page":"e70784","article-title":"Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future","volume":"46","author":"Zeng","year":"2026","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_449","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2174\/1566524022666220316102310","article-title":"Natural Compounds as Integrative Therapy for Liver Protection against Inflammatory and Carcinogenic Mechanisms: FromInduction to Molecular Biology Advancement","volume":"23","author":"Banerjee","year":"2023","journal-title":"Curr. Mol. Med."},{"key":"ref_450","doi-asserted-by":"crossref","first-page":"29400","DOI":"10.1038\/s41598-025-15495-7","article-title":"Metformin and Berberine Synergistically Improve NAFLD via the AMPK\u2013SREBP1\u2013FASN Signaling Pathway","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_451","doi-asserted-by":"crossref","first-page":"e170783","DOI":"10.5812\/ijpr-170783","article-title":"Berberine Alleviates Hepatic Steatosis by Restoring CPT1\u03b1 Histone Acetylation and Modulating HDAC2\/SIRT2","volume":"25","author":"Shi","year":"2026","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_452","doi-asserted-by":"crossref","unstructured":"Lv, Y., Zhao, F., Zhang, Y., Zheng, Z., Hou, C., Jiang, G., Lin, S., Liu, L., and Chen, L. (2026). FGF21 as a Potential Mediator of Ultra-Processed Food-Associated Metabolic Dysfunction-Associated Steatotic Liver Disease and the Protective Effect of Bilberry Extract. Nutrients, 18.","DOI":"10.3390\/nu18152430"},{"key":"ref_453","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jgr.2021.10.005","article-title":"Upregulation of Adiponectin by Ginsenoside Rb1 Contributes to Amelioration of Hepatic Steatosis Induced by High Fat Diet","volume":"46","author":"Li","year":"2022","journal-title":"J. Ginseng Res."},{"key":"ref_454","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41401-024-01412-7","article-title":"Identification of Chikusetsusaponin IVa as a Novel Lysine-Specific Demethylase 1 Inhibitor That Ameliorates High Fat Diet-Induced MASLD in Mice","volume":"46","author":"Liu","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_455","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-024-05011-2","article-title":"The Clinical Efficacy and Safety of Berberine in the Treatment of Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Systematic Review","volume":"22","author":"Nie","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_456","doi-asserted-by":"crossref","first-page":"e2554152","DOI":"10.1001\/jamanetworkopen.2025.54152","article-title":"Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial","volume":"9","author":"Lei","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"ref_457","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ajcnut.2024.05.017","article-title":"Curcumin Supplementation Alleviates Hepatic Fat Content Associated with Modulation of Gut Microbiota-Dependent Bile Acid Metabolism in Patients with Nonalcoholic Simple Fatty Liver Disease: A Randomized Controlled Trial","volume":"120","author":"He","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_458","first-page":"CD015524","article-title":"Silymarin for Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"2025","author":"Wang","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_459","doi-asserted-by":"crossref","first-page":"101045","DOI":"10.1016\/j.gastha.2026.101040","article-title":"Comparative Efficacy of Herbal Products for Improving Liver Enzymes and Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis","volume":"5","author":"Sairaj","year":"2026","journal-title":"Gastro Hep Adv."},{"key":"ref_460","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jhep.2026.01.025","article-title":"Genetic Evidence That FGF21 Signaling Reduces Problematic Alcohol Use and Alcohol-Related Liver Disease","volume":"84","author":"Rosoff","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_461","doi-asserted-by":"crossref","first-page":"101722","DOI":"10.1016\/j.lanepe.2026.101722","article-title":"Diagnostic Innovation and Models of Care to Improve Fibrosis Detection and Risk Stratification in Steatotic Liver Disease","volume":"65","author":"Pugliese","year":"2026","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_462","doi-asserted-by":"crossref","first-page":"e002343","DOI":"10.1136\/bmjgast-2026-002343","article-title":"Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Epidemiology, Risk Stratification and Therapeutics","volume":"13","author":"Li","year":"2026","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_463","doi-asserted-by":"crossref","first-page":"101521","DOI":"10.1016\/j.jhepr.2025.101521","article-title":"Proteomic Signatures Reflect Effects of Semaglutide Treatment for MASH","volume":"7","author":"Schattenberg","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_464","doi-asserted-by":"crossref","unstructured":"Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., and Bril, F. (2024). Endpoints in NASH Clinical Trials: Are We Blind in One Eye?. Metabolites, 14.","DOI":"10.3390\/metabo14010040"},{"key":"ref_465","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/apt.70023","article-title":"Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical Modelling","volume":"61","author":"Shah","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_466","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00535-022-01860-0","article-title":"Systematic Review and Meta-Analysis: Analysis of Variables Influencing the Interpretation of Clinical Trial Results in NAFLD","volume":"57","author":"Ampuero","year":"2022","journal-title":"J. Gastroenterol."},{"key":"ref_467","doi-asserted-by":"crossref","unstructured":"Saliba-Gustafsson, P., H\u00e4rdfeldt, J., Pedrelli, M., and Parini, P. (2025). Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262210881"},{"key":"ref_468","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1042\/CS20250052","article-title":"Gene Regulatory Mechanisms Underlying Sex- and Age-Dependent Pathophysiology of MASLD","volume":"140","author":"Morral","year":"2026","journal-title":"Clin. Sci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:55:44Z","timestamp":1790614544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":468,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198614"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198614","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]}}}